EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An Antibody of the Secreted Isoform of Disintegrin and Metalloprotease 9 (sADAM9) Inhibits Epithelial–Mesenchymal Transition and Migration of Prostate Cancer Cell Lines

Yura Jotatsu, Shain-Ying Sung iD, Ming-Heng Wu, Shunya Takeda, Yuto Hirata iD, Koki Maeda iD, Shiuh-Bin Fang iD, Kuan-Chou Chen iD, Katsumi Shigemura iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25126646 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Yura Jotatsu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, Kobe University Graduate School of Health Sciences, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142, Japan. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Cell Movement, ADAM Proteins, Prostatic Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: kakenhi, Kobe University Strategic International Collaborative Research Grant, Fund for the Promotion of Joint International Research, International Collaborative Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer (PC) is the most common cancer diagnosed in men worldwide. Currently, castration-resistant prostate cancer (CRPC), which is resistant to androgen deprivation therapy, has a poor prognosis and is a therapeutic problem. We investigated the antitumor effects on PC of an antibody neutralizing secreted disintegrin and metalloproteinase domain-containing protein 9 (sADAM9), which is a blood-soluble form. We performed proliferation assays, wound healing assays, invasion assays, Western blot (WB), and an in vivo study in which a sADAM9 neutralizing antibody was administered intratumorally to PC-bearing mice. In invasion assays, the sADAM9 neutralizing antibody significantly inhibited invasion in all cell lines (TRAMP-C2: p = 0.00776, LNCaP: p = 0.000914, PC-3: p = 0.0327, and DU145: p = 0.0254). We examined epithelial–mesenchymal transition (EMT) markers, one of the metastatic mechanisms, in WB and showed downregulation of Slug in TRAMP-C2, LNCaP, and DU145 and upregulation of E-cadherin in TRAMP-C2 and PC-3 by sADAM9 neutralization. In mouse experiments, the sADAM9 neutralizing antibody significantly suppressed tumor growth compared to controls (1.68-fold in TRAMP-C2, 1.89-fold in LNCaP, and 2.67-fold in PC-3). These results suggested that the sADAM9 neutralizing antibody inhibits invasion, migration, and tumor growth in PC. Previous studies examined the anti-tumor effect of knockdown of total ADAM9 or sADAM9, but this study used the new technology of neutralizing antibodies for sADAM9. This may be novel because there was no animal study using a neutralizing antibody for sADAM9 to see the relationship between ADAM9 expression and prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionCell MovementADAM ProteinsProstatic NeoplasmsMaleAnimalsHumansMiceCell Line, TumorAntibodies, NeutralizingCell ProliferationMembrane ProteinsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

ADAM9castration-resistant prostate cancerepithelial–mesenchymal transition (EMT)invasionsecreted ADAM9

Substanzen

ADAM ProteinsADAM9 protein, humanAntibodies, NeutralizingMembrane Proteins

Autor:innen und Institutionen

  • Department of Public Health, Kobe University Graduate School of Health Sciences, 7-10-2 Tomogaoka, Suma-ku, Kobe 654-0142, Japan.
  • International Ph.D. Program for Translational Medicine, College of Medical Sciences and Technology, Taipei Medical University, Taipei 11031, Taiwan.
  • The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, 250 Wu-Hsing St., Taipei 110, Taiwan.
  • Department of Medical Device Engineering, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
  • Department of Urology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.
  • Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Shuang Ho Hospital, Taipei Medical University, 291 Jhong Jheng Road, Jhong Ho District, New Taipei City 23561, Taiwan.

ORCID-Profile: Shain-Ying Sung, Yuto Hirata, Koki Maeda, Shiuh-Bin Fang, Kuan-Chou Chen, Katsumi Shigemura

Förderung

  • kakenhi
  • Kobe University Strategic International Collaborative Research Grant
  • Fund for the Promotion of Joint International Research, International Collaborative Research

Zitieren

APA

Jotatsu, Y., Sung, S. Y., Wu, M. H., Takeda, S., Hirata, Y., Maeda, K., Fang, S. B., Chen, K. C., & Shigemura, K. (2024). An Antibody of the Secreted Isoform of Disintegrin and Metalloprotease 9 (sADAM9) Inhibits Epithelial–Mesenchymal Transition and Migration of Prostate Cancer Cell Lines. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126646

Vancouver

Jotatsu Y, Sung SY, Wu MH, Takeda S, Hirata Y, Maeda K, et al. An Antibody of the Secreted Isoform of Disintegrin and Metalloprotease 9 (sADAM9) Inhibits Epithelial–Mesenchymal Transition and Migration of Prostate Cancer Cell Lines. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126646

BibTeX
@article{Jotatsu2024,
  author = {Jotatsu, Yura and Sung, Shain-Ying and Wu, Ming-Heng and Takeda, Shunya and Hirata, Yuto and Maeda, Koki and Fang, Shiuh-Bin and Chen, Kuan-Chou and Shigemura, Katsumi},
  title = {An Antibody of the Secreted Isoform of Disintegrin and Metalloprotease 9 (sADAM9) Inhibits Epithelial–Mesenchymal Transition and Migration of Prostate Cancer Cell Lines},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25126646}
}
Kostenlos starten →